These treatment guidelines advocated a more individualised approach, and not as much a strict glycated haemoglobin (HbA1c) target, with an emphasis on patient- centred care and shared decision making. Glycaemic targets • Lowering HbA1c to <7.0% is recommended in most patients to reduce the onset and progression of microvascular complications. Because red blood cells in the human body survive for 8-12 weeks before renewal, measuring glycated haemoglobin (or HbA1c) can be used to reflect average blood glucose levels over that duration, providing a useful longer-term gauge of blood glucose control. If your blood sugar levels have been high in recent weeks, your HbA1c will also be greater. The 2015 treatment goals empha-size individualized targets for weight loss, glucose, lipid, and hypertension management. In addition, the 2015 Guidelines promote personalized management plans with a special focus on safety beyond efficacy. When a routine consultation is made for DM manage-ment, these new guidelines advocate taking a comprehen- HbA1c levels should be measured at 3-6 monthly intervals until they are stable or six-monthly intervals once a patient's HbA1c and glucose-lowering therapy are stable. Endorsed Clinical Guidelines 2015/2016 It is important to note that the advice contained within the guidance does not override or replace the individual responsibility of The ADA guidelines recommend that A1C testing be performed at least twice yearly in patients who have achieved stable glycemic control. For those patients who are not at goal or for whom therapy recently changed, quarterly A1C testing is recommended. The ADA now recommends a premeal blood glucose target of 80-130 mg/dL, rather than 70-130 mg/dL, to better reflect new data comparing actual average glucose levels with A1C targets. To provide additional guidance on the successful implementation of continuous glucose monitoring (CGM), the Standards include new recommendations on assessing a For adults on a drug associated with hypoglycaemia, support them to aim for an HbA1c level of 53 mmol/mol (7.0%). [2015] 1.6.8 In adults with type 2 diabetes, if HbA1c levels are not adequately controlled by a single drug and rise to 58 mmol/mol (7.5%) or higher: reinforce advice about diet, lifestyle and adherence to drug treatment and Philadelphia, March 6, 2018 - Patients with type 2 diabetes should be treated to achieve an A1C between 7 percent and 8 percent rather than 6.5 percent to 7 percent, the American College of Physicians (ACP) recommends in an evidence-based guidance statement published today in Annals of Internal Medicine. US Veteran's Administration/Department of Defense Clinical Practice Guidelines HbA1c Recommended for Diagnosis The ADA Clinical Practice Recommendations now recommend using HbA1c to diagnose diabetes using a NGSP-certified method and a cutoff of HbA1c ≥6.5%. POC assay methods are not recommended for diagnosis. A1C or "the A1C test" Your HbA1c should be tested every 3 to 6 months. It might be done more often if your blood glucose levels are changing quickly. You should be told your HbA1c result after each test. The HbA1c result is given in a unit of measurement that is written as 'mmol/mol'. HbA1c used to be given as a percentage (%), so you may still see this. The adequacy of diabetes control should be assessed again at the time of listing for surgery, ideally with a recorded HbA1c < 69 mmol.mol −1 in the previous three months. If it is ≥ 69 mmol.mol −1, elective